Alaunos Therapeutics CEO granted stock in lieu of salary

Alaunos Therapeutics, Inc. CEO Holger Weis received a grant of 4,568 shares of common stock on 2026-07-23 at $1.92 per share, issued in lieu of net salary.

Accepted by SEC EDGAR 07/27/2026 - 04:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Alaunos Therapeutics, Inc. CEO Holger Weis received a grant of 4,568 shares of common stock on 2026-07-23 at $1.92 per share, issued in lieu of net salary. After this compensation-related acquisition, he directly holds 21,120 common shares.

Insider Trade Summary

Grant/Award: 4,568 shares

Grant/Award 1 txn

Insider Weis Holger

Role CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	4,568	$1.92	$9K

Holdings After Transaction: Common Stock — 21,120 shares (Direct)

Footnotes (1)

1. F1. Represents shares of common stock issued in lieu of net salary.

Key Figures

Shares granted: 4,568 shares Grant price: $1.92 per share Holdings after grant: 21,120 shares +1 more

4 metrics

Shares granted 4,568 shares Common stock granted to CEO Holger Weis on 2026-07-23 in lieu of net salary

Grant price $1.92 per share Value per share for common stock issued in lieu of net salary

Holdings after grant 21,120 shares Total direct Alaunos common shares held by CEO Holger Weis after the transaction

Transaction date 2026-07-23 Date of the common stock grant to CEO Holger Weis

Key Terms

in lieu of net salary, Common Stock, Grant, award, or other acquisition

3 terms

in lieu of net salary financial

"Represents shares of common stock issued in lieu of net salary."

Common Stock financial

"Security title reported as Common Stock for this grant."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"Transaction code A is described as Grant, award, or other acquisition."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Alaunos Therapeutics (TCRT) CEO Holger Weis report?

Holger Weis reported receiving 4,568 shares of Alaunos Therapeutics common stock on 2026-07-23 as a grant. The shares were issued in lieu of net salary, meaning they represent stock-based compensation rather than a cash salary payment or open-market share purchase.

How many Alaunos (TCRT) shares did Holger Weis receive and at what value?

Holger Weis received 4,568 Alaunos common shares, valued at $1.92 per share. These shares were issued as compensation in lieu of his net salary, reflecting a stock-based payment instead of cash and increasing his direct equity position in the company.

Is Holger Weis’s Alaunos (TCRT) stock transaction a market purchase?

No. The filing states the 4,568 shares were "issued in lieu of net salary," indicating a compensation grant rather than an open-market purchase. This means the company issued shares to him instead of paying that portion of salary in cash.

How many Alaunos (TCRT) shares does Holger Weis hold after this grant?

Following the grant, Holger Weis directly holds 21,120 shares of Alaunos Therapeutics common stock. This figure reflects his direct ownership immediately after receiving the 4,568-share compensation grant reported in the Form 4 insider transaction filing.

What does "in lieu of net salary" mean in the Alaunos (TCRT) CEO’s filing?

The phrase "in lieu of net salary" means the company issued stock instead of paying that portion of Weis’s salary in cash. He received 4,568 shares of common stock as compensation, converting cash pay into equity rather than making a market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weis Holger

(Last) (First) (Middle)

501 E LAS OLAS BLVD

SUITE 300

(Street)

FORT LAUDERDALE FLORIDA 33301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alaunos Therapeutics, Inc. [ TCRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/23/2026		A		4,568(1)	A	$1.92	21,120	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock issued in lieu of net salary.

	Weis Holger	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)